The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Open accessAbstract
BACKGROUND: Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, we describe the use of the restricted mean survival time as a possible alternative tool in the design and analysis of these trials. METHODS: The restricted mean is a measure of average survival from time 0 to a specified time point, and may be estimated as the area under the survival curve up to that point. We consider the design of such trials according to a wide range of possible survival distributions in the control and research arm(s). The distributions are conveniently defined as piecewise exponential distributions and can be specified through piecewise constant hazards and time-fixed or time-dependent hazard ratios. Such designs can embody proportional or non-proportional hazards of the treatment effect. RESULTS: We demonstrate the use of restricted mean survival time and a test of the difference in restricted means as an alternative measure of treatment effect. We support the approach through the results of simulation studies and in real examples from several cancer trials. We illustrate the required sample size under proportional and non-proportional hazards, also the significance level and power of the proposed test. Values are compared with those from the standard approach which utilizes the logrank test. CONCLUSIONS: We conclude that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial. Restricted mean survival time may provide a practical way forward and deserves greater attention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
(2009) · The Lancet · doi:10.1016/s0140-6736(08)61766-3 · Cited by 1,801
Royston, P., & Parmar, M. K. B. (2002) · Statistics in Medicine · doi:10.1002/sim.1203 · Cited by 1,529
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459
Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 837
Further Development of Flexible Parametric Models for Survival Analysis
Lambert, P. C., & Royston, P. (2009) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0900900206 · Cited by 814
Self-citationRoyston, P., & Parmar, M. K. B. (2011) · Statistics in Medicine · doi:10.1002/sim.4274 · Cited by 585
Self-citation
Cited by
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
Stone, G. W., Kappetein, A. P., Sabik, J. F., Pocock, S. J., Morice, M.-C., Puskas, J., Kandzari, D. E., Karmpaliotis, D., Brown, W. M., Lembo, N. J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909406 · Cited by 797
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
The evolution of lung cancer and impact of subclonal selection in TRACERx
Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., et al. (2023) · Nature · doi:10.1038/s41586-023-05783-5 · Cited by 313
Daniel, R., Zhang, J., & Farewell, D. (2021) · Biometrical Journal · doi:10.1002/bimj.201900297 · Cited by 167
Metadata
- Authors
- Royston, P., & Parmar, M. K.
- Venue
- BMC Medical Research Methodology
- Published
- 2013-12
- Volume
- 13
- Issue
- 1
- Pages
- 152-152
- ISSN
- 1471-2288 (ISSN-L)
- OpenAlex
- W2072013249
- Cited by
- 1,062
- References
- 21
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. https://app.cochat.ai/papers/10.1186/1471-2288-13-152
- The paper
- Royston, P., & Parmar, M. K. (2013). Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Medical Research Methodology. https://doi.org/10.1186/1471-2288-13-152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.